References in periodicals archive ?
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study.
Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
Polymorphisms in the gene coding for cholesteryl ester transfer protein are related to plasma high-density lipoprotein cholesterol and transfer protein activity.
Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma.
The report provides comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation.
Plasma cholesteryl ester transfer protein activity in hyperand hypothyroidism.
Work on other drugs of the same class, known as cholesteryl ester transfer protein (CTEP) inhibitors, continued, and one of these drugs, called evacetrapib, appears to be both safe and effective.
Multiple less common genetic variants explain the association of the cholesteryl ester transfer protein gene with coronary artery disease.
Monotherapy with the cholesteryl ester transfer protein (CETP) inhibitor produced a dose-dependent increase in HDL cholesterol that ranged from 53.